About

I am the founder of Longinus Therapeutics, a Madrid-based precision-medicine biotech. We are developing an intrathecal antisense oligonucleotide (ASO) that lowers CYFIP1 expression in patients with 15q11.2 BP1-BP2 microduplication — a recurrent copy-number variant affecting hundreds of thousands of families worldwide, with no approved targeted treatment.

I started the program in 2026 after my daughter Emma was diagnosed. The science exists: the CYFIP1 gene is well-characterized, the downstream pathways are druggable, and the regulatory path is precedented by Ionis's ATTUNE trial (MECP2 duplication) and ION582 (Angelman syndrome). What was missing was a focused program. We are building it.

Current program focus:

• CYFIP1-targeting MOE/DNA gapmer ASO — design, screening, IND-enabling tox
• Patient iPSC-derived cortical neurons as the human validation model
• CSF CYFIP1 biomarker development (SIMOA) and EEG signature characterization
• Natural history study in collaboration with Simons Searchlight
• Epigenetic silencing of CYFIP1 — on the roadmap as future work

Background

Before Longinus I worked in software and applied research. The technical groundwork for the CYFIP1 program — AlphaFold3 structural validation, virtual screening of approved-drug libraries against the CYFIP1 surface, an internal ASO design pipeline — was built personally over the months leading up to incorporation. The company now collaborates with academic partners in the Netherlands, Switzerland, the UK, and Spain.

Contact

Reach me at [email protected]. Company site: longinus.bio. I am happy to hear from researchers, families with a 15q11.2 BP1-BP2 diagnosis, prospective investors, and potential pharma partners.